Is ABT a good stock to buy? We came across a bullish thesis on Abbott Laboratories on Compounding Dividends’s Substack by TJ Terwilliger. In this article, we will summarize the bulls’ thesis on ABT. Abbott Laboratories’s share was trading at $109.56 as of March 6th. ABT’s trailing and forward P/E were 29.45 and 19.30, respectively according to Yahoo Finance.
Abbott Laboratories (ABT) is a diversified global healthcare company with a presence across medical devices, diagnostics, nutrition, and established pharmaceuticals, serving both developed and emerging markets. Its medical devices and diagnostics segments drive nearly 70% of revenue, with high-margin products like the FreeStyle Libre glucose monitor and heart repair devices underpinning a durable competitive moat through patents and high switching costs.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The nutrition segment, anchored by trusted brands like Similac and Ensure, benefits from strong customer loyalty, while branded generics in emerging markets provide steady growth exposure. Despite this, Abbott faces near-term challenges, including legal liabilities over specialty infant formula, weakened demand following price increases, declining COVID-testing revenues, and pricing pressures in China, which have contributed to a stock decline of roughly 15% this year and pushed the dividend yield toward 2.4%. Management, led by CEO Robert B. Ford, has a track record of navigating complex markets and acquisitions, including the $21 billion Exact Sciences deal aimed at entering cancer diagnostics.
Abbott’s balance sheet is strong, with a debt-to-equity ratio of 30%, an interest coverage ratio of 75, and robust free cash flow generation, enabling continued dividend growth—54 consecutive years and a 5-year CAGR of 9.4%. While near-term headwinds create some uncertainty, the combination of secular tailwinds in chronic disease management, an aging population, and emerging middle-class markets positions Abbott favorably.
For long-term investors seeking resilient healthcare exposure and reliable dividends, Abbott represents a compelling opportunity, offering a mix of defensive characteristics, innovation-driven growth, and a proven capital allocation track record that could support upside as market pressures normalize.
Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel in May 2025, highlighting broad growth across cardiovascular and diabetes segments and the upcoming diabetes business spin-off. MDT’s stock price has appreciated by 12.66% since our coverage. TJ Terwilliger shares a similar view but emphasizes Abbott Laboratories’ (ABT) diversified healthcare model, strong medical device moat, and resilient dividend growth, offering long-term upside.
Abbott Laboratories is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 71 hedge fund portfolios held ABT at the end of the fourth quarter which was 68 in the previous quarter. While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
